Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arcus Biosciences

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

72 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Oncologia
Arcus Biosciences Announces New Employment Inducement Grants
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
26/02/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Oncologia
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
11/02/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
26/01/2026
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Finanza
Arcus Biosciences Announces New Employment Inducement Grants
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
07/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Web e Social Network
Eventi
Industria
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
18/12/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
12/12/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0
09/12/2025
Mercato azionario
Finanza
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Arcus Biosciences Announces New Employment Inducement Grants
Fonte
Arcus Biosciences
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0